Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Pembrolizumab + Pemetrexed in elderly patients with
non-squamous non-small cell lung cancer with Programmed cell death (PD) -ligand1 (L1) tumor
proportion score (TPS) of less than 50%.
Phase:
Phase 2
Details
Lead Sponsor:
National Hospital Organization Nagoya Medical Center
Collaborators:
Central Japan Lung Study Group Merck Sharp & Dohme Corp.